- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Deferred appraisal of D5.
- Process:
- STA Standard
- ID number:
- 12518
Provisional Schedule
- Committee meeting: 1:
- 04 February 2027
- Expected publication:
- 07 April 2027
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- Johnson & Johnson Innovative Medicine (ciltacabtagene autoleucel)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Myeloma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Geriatrics Society
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Blood and Marrow Transplantation and Cellular Therapy
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Accord Healthcare (pomalidomide)
- Amarox (pomalidomide)
- Amgen (carfilzomib)
- Aspire Pharma (bortezomib)
- Aurobindo Pharma (bortezomib)
- Biotech Pharma (bortezomib)
- Dr. Reddy’s Laboratories (bortezomib)
- GlaxoSmithKline (belantamab mafodotin)
- Grindeks Kalceks (pomalidomide)
- Johnson & Johnson Innovative Medicine (bortezomib, daratumumab, teclistamab, talquetamab)
- Menarini Stemline (selinexor)
- MSN Laboratories Europe (bortezomib)
- pharmaand GmbH (panobinostat)
- Ranbaxy (bortezomib) (Sun Pharma)
- Sandoz (bortezomib)
- Sanofi (isatuximab)
- Thornton & Ross (bortezomib, pomalidomide)
- Wockhardt UK (pomalidomide)
- Zentiva Pharma (pomalidomide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematology
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Institute for Health Research
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 July 2026 | In progress. Invitation to participate has been issued. |
| 08 July 2026 | Invitation to participate |
| 01 July 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 01 July 2026 | This is the deferred appraisal of D5. Scoping documents can be found on the record for D5. The appraisal is expected to begin in early July 2026. - Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual